Journal
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
Volume 10, Issue 2, Pages 208-214Publisher
BENTHAM SCIENCE PUBL
DOI: 10.2174/187152711794480401
Keywords
Neurodegeneration; neuroprotective drugs; cellular screening
Categories
Funding
- Spanish Ministry of Health [SAF 2006-02424]
- Ciberned [CB06/05/0035]
- Noscira [2008/285]
- Comunidad de Madrid [SAL/0202/2006]
- Fundacion Marcelino Botin
- Fundacion CIEN [PI 008/09]
- Fundacion Ramon Areces
- CIBERNED (an initiative of the ISCIII)
- Plan Nacional DGCYT [DGCYT SAF2009-12249-C02-01, CDTI-CENIT-INGENIO 2010]
- EU [FP7-2009-CT222887]
- Fundacion Areces
Ask authors/readers for more resources
Few targets for neuroprotection have been defined in Alzheimer's disease (AD). Recent data from the role of Wnt, insulin-like growth factor-1 and estradiol pathways in AD suggest some therapeutic targets for disease treatment, and have led us to evaluate the common factors in these pathways as further candidate targets. These data have led us to propose that glycogen synthase kinase-3 (GSK-3) inhibition appears to be a common feature of these pathways. Besides, considering that GSK-3 activation seems to be correlated with neurodegeneration, its selection as a relevant target appears obvious. The capacity of different GSK-3 inhibitors to prevent amyloid beta-peptide neurotoxicity and tau phosphorylation has been evaluated in order to develop novel clinical and therapeutic approaches. Different approaches could be used to search for new neuroprotective compounds. The most classical of these is to first define the target and then design a specific in vitro screening assay for it. Alternatively, a cell model of cell culture could be used as a primary screen. Following this rationale, we have used a combined approach in which we first used an in vitro system to select compounds able to inhibit recombinant GSK3. Subsequently, we subjected the candidate compounds to three consecutive cell-based complementary screening assays. First, cell viability was assessed using a neuroblastoma cell line before assaying the capacity of the compounds to reduce tau phosphorylation. Finally, we designed a neuronal cell model of apoptosis using the phosphatidylinositol kinase-3 inhibitor LY294002. Finally, we summarize several new compounds with neuroprotective properties.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available